Up to 5% of patients using the Daytrana transdermal patch, used for ADHD treatment, have reported trouble removing the release liner from the sticky part of the patch. The patches have been withdrawn following these reports of application difficulty. While this has nothing to do with the release of the drug into the body, the manufacturer decided to withdraw the product anyway.
Shire, the UK company whom holds the global license for Daytrana, says the patches could be used as long as they weren't damaged. Improvements are in the works to fix the problem, and the new patches should replace the ones being withdrawn. Daytrana is the first and only transdermal medication approved by the FDA to treat ADHD symptoms, and was approved by the FDA last year for children with the disorder between ages 6 to 12.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment